{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:09Z","timestamp":1761947589704},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T00:00:00Z","timestamp":1265932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00520-009-0749-5","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T21:33:15Z","timestamp":1265923995000},"page":"1305-1312","source":"Crossref","is-referenced-by-count":10,"title":["Bone pain reduction in patients with metastatic breast cancer treated with ibandronate\u2013results from a post-marketing surveillance study"],"prefix":"10.1007","volume":"18","author":[{"given":"Ingo J.","family":"Diel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H. A.","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Bernd","family":"Sittig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Meden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maasberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sandermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,12]]},"reference":[{"key":"749_CR1","unstructured":"World Health Organization (1996) WHO Guidelines: cancer pain relief. World Health Organization, Geneva"},{"key":"749_CR2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thurlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420\u2013432","journal-title":"Ann Oncol"},{"key":"749_CR3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306\u2013312","journal-title":"Pain"},{"key":"749_CR4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"749_CR5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133\u20131137","journal-title":"Br J Cancer"},{"key":"749_CR6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676\u20131679 discussion 1676\u20131679","journal-title":"N Engl J Med"},{"key":"749_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"749_CR8","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","volume":"14","author":"PF Conte","year":"1996","unstructured":"Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 14:2552\u20132559","journal-title":"J Clin Oncol"},{"key":"749_CR9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00520-007-0244-9","volume":"15","author":"IJ Diel","year":"2007","unstructured":"Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15:1243\u20131249","journal-title":"Support Care Cancer"},{"key":"749_CR10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","volume":"40","author":"IJ Diel","year":"2004","unstructured":"Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704\u20131712","journal-title":"Eur J Cancer"},{"key":"749_CR11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0885-3924(92)90101-M","volume":"7","author":"DS Ernst","year":"1992","unstructured":"Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E (1992) A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4\u201311","journal-title":"J Pain Symptom Manage"},{"key":"749_CR12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.330.7494.769","volume":"330","author":"MC Gainford","year":"2005","unstructured":"Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. Brit Med J 330:769\u2013773","journal-title":"Brit Med J"},{"key":"749_CR13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785\u20131791","journal-title":"N Engl J Med"},{"key":"749_CR14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(74)90884-8","volume":"2","author":"EC Huskisson","year":"1974","unstructured":"Huskisson EC (1974) Measurement of pain. Lancet 2:1127\u20131131","journal-title":"Lancet"},{"key":"749_CR15","unstructured":"Johnson KB, Gable P, Kaime EM, Luiken G, Castillos T, Hu J (2003) Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 22: abstr 2968"},{"key":"749_CR16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.1995.13.4.929","volume":"13","author":"N O'Rourke","year":"1995","unstructured":"O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA (1995) Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929\u2013934","journal-title":"J Clin Oncol"},{"key":"749_CR17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"749_CR18","doi-asserted-by":"crossref","unstructured":"Pal SK, Gupta R, Bernstein L, Mortimer J (2008) Lack of survival benefit in metastatic breast cancer with newer chemotherapy agents: The City of Hope cancer experience. ASCO 2008 Breast Cancer Symposium; Washington, DC. Abstract #95","DOI":"10.1200\/jco.2008.26.15_suppl.17510"},{"key":"749_CR19","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev: CD003474","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"749_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","volume":"26","author":"M Pecherstorfer","year":"2006","unstructured":"Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstrom B (2006) Long-term safety of intravenous ibandronic acid for up to 4\u00a0years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26:315\u2013322","journal-title":"Clin Drug Investig"},{"key":"749_CR21","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"749_CR22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0749-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0749-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:01:55Z","timestamp":1559095315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0749-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,12]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0749-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,12]]}}}